GMAB Stock Overview
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
GMAB passed our risk checks.
Genmab A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.268.30 |
52 Week High | kr.391.00 |
52 Week Low | kr.248.40 |
Beta | 0.78 |
1 Month Change | -1.36% |
3 Month Change | 0.94% |
1 Year Change | -28.05% |
3 Year Change | -13.34% |
5 Year Change | n/a |
Change since IPO | -15.52% |
Recent News & Updates
Recent updates
Shareholder Returns
GMAB | AT Biotechs | AT Market | |
---|---|---|---|
7D | -3.3% | -2.6% | -0.3% |
1Y | -28.1% | -12.3% | 2.4% |
Return vs Industry: GMAB underperformed the Austrian Biotechs industry which returned -12.4% over the past year.
Return vs Market: GMAB underperformed the Austrian Market which returned 1.8% over the past year.
Price Volatility
GMAB volatility | |
---|---|
GMAB Average Weekly Movement | 4.3% |
Biotechs Industry Average Movement | 7.6% |
Market Average Movement | 3.4% |
10% most volatile stocks in AT Market | 5.4% |
10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: GMAB has not had significant price volatility in the past 3 months.
Volatility Over Time: GMAB's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 2,204 | Jan G.J. van Winkel | www.genmab.com |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
Genmab A/S Fundamentals Summary
GMAB fundamental statistics | |
---|---|
Market cap | €17.37b |
Earnings (TTM) | €583.23m |
Revenue (TTM) | €2.21b |
29.8x
P/E Ratio7.9x
P/S RatioIs GMAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GMAB income statement (TTM) | |
---|---|
Revenue | kr.16.47b |
Cost of Revenue | kr.226.00m |
Gross Profit | kr.16.25b |
Other Expenses | kr.11.90b |
Earnings | kr.4.35b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | 66.95 |
Gross Margin | 98.63% |
Net Profit Margin | 26.42% |
Debt/Equity Ratio | 0% |
How did GMAB perform over the long term?
See historical performance and comparison